PAKOLA STEVE
Chief Medical Officer
PAKOLA STEVE has filed 8 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2026. 8 of those filings fall inside the rolling window. Most recent filing: Aug 4, 2026.
On the most recent filing, PAKOLA STEVE is listed as Chief Medical Officer at REGENXBIO Inc. Inside the rolling window, PAKOLA STEVE reported no open-market purchases and 5 open-market sales totaling $940K in RGNX. The largest disclosed transaction in the window is a sale of 36,725 RGNX shares on Jul 1, 2026, worth $472K.
Companies traded
Other insiders at RGNX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$940K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has PAKOLA STEVE made?
PAKOLA STEVE has filed 8 SEC Form 4 filings (11 transaction rows) across 1 company since 2026.
Which companies does PAKOLA STEVE trade?
PAKOLA STEVE has filed SEC Form 4 disclosures for 1 company, including RGNX.
When was PAKOLA STEVE's most recent SEC Form 4 filing?
PAKOLA STEVE's most recent SEC Form 4 filing on Tracefour is dated Aug 4, 2026.
What is PAKOLA STEVE's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, PAKOLA STEVE is listed as Chief Medical Officer.
What is PAKOLA STEVE's total buy and sell value in the current window?
Inside the rolling retention window, PAKOLA STEVE bought $0 and sold $940K based on SEC Form 4 filings.
What was PAKOLA STEVE's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 36,725 RGNX shares on 2026-07-01, worth $472K, per SEC Form 4 filings.